We are excited to share that our latest work from the lab aimed at understanding how the tRNA nuclease SLFN11 is activated in response to DNA damage and replication stress has just been published in @natcellbio.nature.com! Open access link: www.nature.com/articles/s41... (1/9)

‼️ Excited to share our new paper out now in @science.org ‼️ We describe a new tetrameric RAD51 paralog complex – XRCC3-RAD51C-RAD51D-XRCC2 – which caps the end of RAD51 filaments. Link: www.science.org/doi/epdf/10.... Thread ⬇️ (1/8)

🧬 Preprint alert! "Distinct ATRX functions cooperate with 9-1-1 and CST complexes to safeguard replication and telomere integrity." Read the manuscript here 👉 www.biorxiv.org/content/10.1...

Distinct ATRX functions cooperate with 9-1-1 and CST complexes to safeguard replication and telomere integrity

Mutations in the ATRX chromatin remodeller predispose to a developmental genetic disorder and cancer, but how it safeguards genome and telomere stability remains unresolved. Here, we uncover critical ...

biorxiv.org

New preprint from the lab led by @ssegurabayona.bsky.social identifying SLFN11 activity as a barrier to ALT establishment.

Sandra Segura-Bayona@ssegurabayona.bsky.social · 11mo ago

🚀 New preprint alert! We uncover SLFN11 as a molecular gatekeeper that restricts alternative lengthening of telomeres (ALT) by sensing telomere-associated replication stress and triggering apoptosis. 📄 Read the manuscript here: www.biorxiv.org/content/10.1...

🚀 New preprint alert! We uncover SLFN11 as a molecular gatekeeper that restricts alternative lengthening of telomeres (ALT) by sensing telomere-associated replication stress and triggering apoptosis. 📄 Read the manuscript here: www.biorxiv.org/content/10.1...

SLFN11 restricts escape from telomere crisis to prevent alternative lengthening of telomeres

The tRNA nuclease SLFN11 is epigenetically silenced in ~50% of treatment-naive tumours and is the strongest predictor of chemoresistance but why it is frequently inactivated in cancer is unknown. To a...

biorxiv.org

Save de date! Join us at @cabimer.bsky.social on October 17th for the @GenomaHubCSIC Workshop in "Genome Dynamics in Development and Disease". Slots available for talks! Registration opens soon!!

We are looking to recruit three posts at the @crick.ac.uk in structural biology, cell biology, and pharmacology to join a 20+ strong multidisciplinary team focused on delivering the first precision medicines for the treatment of ALT cancers. Interested? Please check out the advertised jobs below:

Read our Q&A with Simon Boulton (@boultonlab.bsky.social), a group leader here at the Crick who co-founded the company Artios in 2016. Artios is a biotech company that develops cancer treatments that target DNA damage response pathways. www.crick.ac.uk/news-and-fea...

From the lab to the clinic: developing the next generation of precision cancer therapies

Crick group leader Simon Boulton co-founded Artios in 2016, a spin-out from Cancer Research UK’s Commercial Partnerships, where he is now VP of Science Strategy. Artios develops cancer treatments that...

crick.ac.uk

Artios Pharma presented data on its ATR inhibitor (blocks a key DNA damage response enzyme) at #AACR25 today. 50% response (tumor shrinkage) in patients whose tumors lacked a counterpart DNA repair enzyme called ATM. Read more in my story for @endpts.com endpts.com/artios-cance...

Artios drug exploits ‘replication stress’ in cancer, shrinking subset of tumors in early study

Artios Pharma, a startup developing drugs that weaken a tumor’s ability to maintain its DNA, announced positive results in a subset of patients with advanced cancer.

endpts.com

Exciting results were presented by Artios Pharma at the AACR meeting from their STELLA Phase 1/2a study using their ATR inhibitor ART0380 to target ATM low/negative tumours: www.artios.com/press-releas...

Artios Pharma Reports Differentiated Clinical Activity in STELLA Phase 1/2a Study for Lead Program ART0380 at the American Association for Cancer Research (AACR) Annual Meeting 2025 - Artios Pharma

ART0380 in combination with low-dose irinotecan demonstrated a 50% confirmed overall response rate (cORR) in patients with Ataxia-Telangiectasia Mutated (ATM)-negative1 solid tumors at the recommended...

artios.com